Abstract
This review presents the clinical pharmacokinetics of imatinib mesylate. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed.
MeSH terms
-
Administration, Oral
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacokinetics*
-
Benzamides
-
Drug Interactions
-
Enzyme Inhibitors / therapeutic use*
-
Gastrointestinal Neoplasms / drug therapy*
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Piperazines / administration & dosage
-
Piperazines / pharmacokinetics*
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Pyrimidines / administration & dosage
-
Pyrimidines / pharmacokinetics*
-
Stromal Cells / drug effects
Substances
-
Antineoplastic Agents
-
Benzamides
-
Enzyme Inhibitors
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Protein-Tyrosine Kinases